Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03904277 · ClinicalTrials.gov registry record
Does Patent Foramen Ovale Size Matter in Men and Women
A clinical trial of Patent Foramen Ovale, sponsored by University of Oregon.
- Completed
- Registry status
- 28
- Enrollment target
- 1
- Study location
NCT03904277: Completed study of Patent Foramen Ovale, sponsored by University of Oregon.
NCT03904277 is a study of Patent Foramen Ovale that has completed, run by University of Oregon. The registered enrollment target is 28 participants, below the 417-participant average among 7 other Patent Foramen Ovale trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03904277, a study of Patent Foramen Ovale, has completed, sponsored by University of Oregon.
- COMPLETED
- Registry status
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
A patent foramen ovale (PFO) is present in \~30% of the general population. The PFO has historically been considered to be trivial. However, recent work by the investigator's group and others has identified that, compared to individuals without a PFO, those with a PFO have worse pulmonary gas exchange efficiency, have a higher core body temperature, blunted ventilatory responses to chronic hypoxia and acute carbon dioxide and increased susceptibility to altitude illnesses such as acute mountain sickness, and high altitude pulmonary edema (Lovering, Elliott \& Davis J Appl Physiol 2016). Specific to this application,subjects with a PFO may have worse pulmonary gas exchange efficiency because a PFO is a potential source of right-to-left shunt that will make pulmonary gas exchange efficiency worse. If true, then this may negatively impact exercise capacity and/or exercise tolerance. Further, in those with a PFO compared to those without, preliminary work from the investigator's lab indicates that there may be an effect of PFO size on pulmonary gas exchange efficiency. This is such that those with a large PFO (grade 3 or higher) display significantly worse gas exchange efficiency compared to those with a small (grade 2 or lower) or no PFO,even at low exercise workloads. Additionally, the investigators were curious as to whether there would be a sex effect, but due to logistical constraints, the investigators were unable to recruit an equal number of female and male subjects. Thus, in addition to the potential size effect on the investigators outcome measures, the investigators would like to build on this work by examining the potential effect of biological sex. Although a PFO has been traditionally considered to have a minimal impact of physiology and pathophysiology, emerging evidence suggests this may not be the case. The investigator's lab is focused on understanding how and why a relatively small hole in the heart (PFO) can have a relatively large impact on cardiopu
Primary Outcome
difference in the partial pressure of oxygen between the alveoli (calculated) and arterial blood (direct measure)
Conditions Studied
Study Locations (1)
Oregon
- Cardiorespiratory and Pulmonary Physiology Lab - Eugene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2018-10-01 |
| Est. Completion | 2023-01-25 |
What the finished NCT03904277 record still lists
NCT03904277 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 417-participant average among 7 other Patent Foramen Ovale trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Patent Foramen Ovale appearing as the primary indexed condition, and to 0 interventions.
NCT03904277 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT03904277 about?
NCT03904277 is a clinical study titled "Does Patent Foramen Ovale Size Matter in Men and Women". A patent foramen ovale (PFO) is present in \~30% of the general population. The PFO has historically been considered to be trivial. However, recent work by the investigator's group and others has identified that, compared to individuals without a PFO, those with a PFO have worse pulmonary gas exchan...
What is the current status of trial NCT03904277?
This trial is currently completed. The enrollment target is 28 participants. The study started on 2018-10-01. Estimated completion is 2023-01-25.
What conditions does trial NCT03904277 study?
This clinical trial studies the following conditions: Patent Foramen Ovale.
Who is sponsoring clinical trial NCT03904277?
This trial is sponsored by University of Oregon, which has 63 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03904277 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Patent Foramen Ovale
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Encore PFO Closure Device - The PerFOrm Trial
RECRUITING · NA
-
Early Feasibility Study (EFS) Evaluating Percutaneous Repair of the Atrial Septum With a Novel PFO Occluder: The PROTEA-PFO Study
RECRUITING · NA
-
AMPLATZER PFO Occluder Post Approval Study
ACTIVE NOT RECRUITING · NA
-
Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion
ACTIVE NOT RECRUITING · NA
-
Is Blood Flow Through IPAVA and PFO Related to Breath-hold and SCUBA Diving-induced Pulmonary Hypertension?
COMPLETED · Early Phase 1
-
Comorbidities Associated With Migraine and Patent Foramen Ovale (CAMP)
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI